SCHEMBL1695274

SCHEMBL1695274

CCN(CC)CCCCN(C(=O)O)c1ccnc2cc(F)ccc12

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.43
HSD17B10 Q99714 2/20 0.43
MAPT P10636 1/20 0.43
NSD1 Q96L73 1/20 0.43
CHRM2 P08172 2/20 0.40
CHRM4 P08173 2/20 0.40
CHRM5 P08912 2/20 0.40
ADRA2A P08913 2/20 0.40
CHRM1 P11229 2/20 0.40
ADRA2B P18089 2/20 0.40
ADRA2C P18825 2/20 0.40
CHRM3 P20309 2/20 0.40
KCNH2 Q12809 2/20 0.40
TMEM97 Q5BJF2 2/20 0.40
SIGMAR1 Q99720 2/20 0.40
ACE2 Q9BYF1 2/20 0.40
CYP2D6 P10635 1/20 0.40
CYP2C19 P33261 1/20 0.40
TDP1 Q9NUW8 1/20 0.40
PRNP P04156 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1695273 0.93 CDK1 (0.47) KDM4EHSD17B10MAPTNSD1CHRM2
SCHEMBL1550842 0.87 KDM4E (0.44) KDM4EHSD17B10MAPTNSD1CHRM2
SCHEMBL1550998 0.86 KDM4E (0.58) KDM4EHSD17B10MAPTNSD1CHRM2
SCHEMBL1695452 0.83 CHRM2 (0.43) KDM4EHSD17B10MAPTNSD1CHRM2
SCHEMBL5071096 0.83 HRH3 (0.47) KDM4EKCNH2CYP2D6HRH3LMNA
SCHEMBL1695719 0.83 KDM4E (0.46) KDM4EHSD17B10MAPTNSD1CHRM2
SCHEMBL1695270 0.81 CDK1 (0.47) KDM4EHSD17B10MAPTNSD1CHRM2
SCHEMBL1550687 0.80 CDK1 (0.62) KDM4EHSD17B10MAPTNSD1CHRM2
SCHEMBL5074576 0.78 CDK1 (0.49) KDM4EHSD17B10MAPTNSD1CHRM2
SCHEMBL5074650 0.78 HRH3 (0.37) KDM4EHSD17B10MAPTNSD1CHRM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1581167-A4 COMPOSITIONS AND METHODS FOR THE TREATMENT OF PARKINSON'S DISEASE AND TARDIVE DYSKINESIAS ALPHA RES GROUP LLC (US) 2008-10-29 EP claimed
JP-2006514917-A 2006-05-18 JP claimed
EP-1581167-A2 COMPOSITIONS AND METHODS FOR THE TREATMENT OF PARKINSON'S DISEASE AND TARDIVE DYSKINESIAS Alpha Research Group, LLC (US) 2005-10-05 EP claimed
WO-2004004660-A2 COMPOSITIONS AND METHODS FOR THE TREATMENT OF PARKINSON’S DISEASE AND TARDIVE DYSKINESIAS ALPHA RESEARCH GROUP, L.L.C. (US) 2004-01-15 WO claimed
EP-3684376-A1 NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND METHODS OF INDUCING EXON SKIPPING Avidity Biosciences, Inc. (US) 2020-07-29 EP disclosed
WO-2019060775-A1 NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND METHODS OF INDUCING EXON SKIPPING AVIDITY BIOSCIENCES LLC (US) 2019-03-28 WO disclosed
EP-2585113-A1 OPTIMIZED IN VIVO DELIVERY SYSTEM WITH ENDOSOMOLYTIC AGENTS FOR NUCLEIC ACID CONJUGATES DNA Therapeutics (FR) 2013-05-01 EP disclosed
WO-2012163814-A1 CANCER TREATMENT BY COMBINING DNA MOLECULES MIMICKING DOUBLE STRAND BREAKS WITH HYPERTHERMIA INSTITUT CURIE (FR) 2012-12-06 WO disclosed
WO-2011161075-A1 OPTIMIZED IN VIVO DELIVERY SYSTEM WITH ENDOSOMOLYTIC AGENTS FOR NUCLEIC ACID CONJUGATES DNA THERAPEUTICS (FR) 2011-12-29 WO disclosed
EP-1581167-A4 COMPOSITIONS AND METHODS FOR THE TREATMENT OF PARKINSON'S DISEASE AND TARDIVE DYSKINESIAS ALPHA RES GROUP LLC (US) 2008-10-29 EP disclosed
EP-1581167-A2 COMPOSITIONS AND METHODS FOR THE TREATMENT OF PARKINSON'S DISEASE AND TARDIVE DYSKINESIAS Alpha Research Group, LLC (US) 2005-10-05 EP disclosed
WO-2004004660-A2 COMPOSITIONS AND METHODS FOR THE TREATMENT OF PARKINSON’S DISEASE AND TARDIVE DYSKINESIAS ALPHA RESEARCH GROUP, L.L.C. (US) 2004-01-15 WO disclosed